FRANKFURT -Roche's third-quarter sales gained a currency-adjusted 9%, beating market expectations, on higher prescriptions of once-monthly haemophilia shot Hemlibra and recently launched eye drug Vabysmo.
Group sales of 15.14 billion Swiss francs surpassed an analysts' consensus estimate of 14.9 billion francs, based on LSEG data. The Swiss drugmaker reaffirmed on Wednesday it expects growth in 2024 adjusted earnings per share in the"high single-digit range", excluding the effect of currency swings and resolution of tax disputes in 2023.Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.